Matrix metalloproteinase-7 and -13 expression associate to cisplatin resistance in head and neck cancer cell lines.

[1]  Kuo-Feng Huang,et al.  A novel role of thrombospondin-1 in cervical carcinogenesis: inhibit stroma reaction by inhibiting activated fibroblasts from invading cancer. , 2008, Carcinogenesis.

[2]  W. May,et al.  c-Myc and Caspase-2 Are Involved in Activating Bax during Cytotoxic Drug-induced Apoptosis* , 2008, Journal of Biological Chemistry.

[3]  M. Fraser,et al.  Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function , 2008, International journal of cancer.

[4]  P. Nguyen,et al.  DNMT1 as a Molecular Target in a Multimodality-Resistant Phenotype in Tumor Cells , 2008, Molecular Cancer Research.

[5]  J. Raffetto,et al.  Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. , 2008, Biochemical pharmacology.

[6]  J. Vermorken,et al.  Neoadjuvant chemotherapy in head and neck cancer: should it be revisited? , 2007, Cancer letters.

[7]  A. Culhane,et al.  Common Molecular Mechanisms of Mammary Gland Development and Breast Cancer , 2007, Cellular and Molecular Life Sciences.

[8]  Jeremy MG Taylor,et al.  Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer. , 2007, International journal of radiation oncology, biology, physics.

[9]  C. West,et al.  Clinical and biological factors affecting response to radiotherapy in patients with head and neck cancer: a review , 2007, Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery.

[10]  M. Sundvall,et al.  Concomitant chemoirradiation with vinorelbine and gefitinib induces additive effect in head and neck squamous cell carcinoma cell lines in vitro. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  Roland C Grafström,et al.  Bioinformatics processing of protein and transcript profiles of normal and transformed cell lines indicates functional impairment of transcriptional regulators in buccal carcinoma. , 2007, Journal of proteome research.

[12]  K. Uzawa,et al.  Establishment and characterization of a cisplatin-resistant cell line, KB-R, derived from oral carcinoma cell line, KB. , 2007, International journal of oncology.

[13]  Jake Yue Chen,et al.  A Systems Biology Approach to the Study of cisplatin Drug Resistance in Ovarian cancers , 2007, J. Bioinform. Comput. Biol..

[14]  M. Dolan,et al.  Molecular mechanisms of resistance and toxicity associated with platinating agents. , 2007, Cancer treatment reviews.

[15]  A. Dietz,et al.  Protein microarrays for the detection of biomarkers in head and neck squamous cell carcinomas. , 2007, Human pathology.

[16]  T. Osaki,et al.  The involvement of hypoxia‐inducible factor‐1α in the susceptibility to γ‐rays and chemotherapeutic drugs of oral squamous cell carcinoma cells , 2007 .

[17]  D. Fishman,et al.  Matrilysin over-expression in MCF-7 cells enhances cellular invasiveness and pro-gelatinase activation. , 2006, Cancer letters.

[18]  Maurice P H M Jansen,et al.  Molecular profiling of platinum resistant ovarian cancer , 2006, International journal of cancer.

[19]  P. Kronqvist,et al.  Association between high collagenase‐3 expression levels and poor prognosis in patients with head and neck cancer , 2006, Head & neck.

[20]  Gillian Murphy,et al.  Structure and function of matrix metalloproteinases and TIMPs. , 2006, Cardiovascular research.

[21]  Tze‐Chien Chen,et al.  Concurrent Cisplatin-Based Chemoradiation for Cervical Carcinoma: Tumor Response, Toxicity, and Serum Cytokine Profiles , 2006, Cancer investigation.

[22]  J. Werner,et al.  RT-PCR expression profiling of matrix metalloproteinases and their specific inhibitors in cell lines and fresh biopsies of squamous cell carcinomas of the head and neck. , 2005, In vivo.

[23]  K. Hui,et al.  A microarray study to characterize the molecular mechanism of TIMP-3-mediated tumor rejection. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  D. Fishman,et al.  Matrilysin (MMP‐7) promotes invasion of ovarian cancer cells by activation of progelatinase , 2005, International journal of cancer.

[25]  T. Boulikas,et al.  Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review). , 2004, Oncology reports.

[26]  Tetsuya Horiuchi,et al.  E-cadherin-dependent intercellular adhesion enhances chemoresistance. , 2003, International journal of molecular medicine.

[27]  J. Varani,et al.  Vascular expression of matrix metalloproteinase-13 (collagenase-3) in basal cell carcinoma. , 2003, Experimental and molecular pathology.

[28]  A I Saeed,et al.  TM4: a free, open-source system for microarray data management and analysis. , 2003, BioTechniques.

[29]  W. Bode,et al.  Structural Basis of the Matrix Metalloproteinases and Their Physiological Inhibitors, the Tissue Inhibitors of Metalloproteinases , 2003, Biological chemistry.

[30]  Gillian Murphy,et al.  Metalloproteinase inhibitors: biological actions and therapeutic opportunities , 2002, Journal of Cell Science.

[31]  T. Ishikawa,et al.  MMP-7 (matrilysin) accelerated growth of human umbilical vein endothelial cells. , 2002, Cancer letters.

[32]  P. Thall,et al.  Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck , 2001, Cancer.

[33]  S. Zucker,et al.  Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment , 2000, Oncogene.

[34]  P. Brown.  Ongoing trials with matrix metalloproteinase inhibitors , 2000, Expert opinion on investigational drugs.

[35]  C. Boshoff,et al.  Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer , 2000, British Journal of Cancer.

[36]  M. Ehrengruber,et al.  Quantitative real-time PCR for the measurement of feline cytokine mRNA , 1999, Veterinary Immunology and Immunopathology.

[37]  R. Giavazzi,et al.  MMP Inhibitors: Experimental and Clinical Studies , 1999, The International journal of biological markers.

[38]  D. Hanahan,et al.  Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. , 1999, Science.

[39]  K. Roberg,et al.  Polymorphism of FGFR4 in cancer development and sensitivity to cisplatin and radiation in head and neck cancer. , 2009, Oral oncology.

[40]  M. Fu,et al.  Adenovirus carrying TIMP-3: a potential tool for cervical cancer treatment. , 2008, Gynecologic oncology.

[41]  Jan Kitajewski,et al.  Wnt/β-Catenin Signaling Induces Proliferation, Survival and Interleukin-8 in Human Endothelial Cells , 2005, Angiogenesis.

[42]  B. Lindeman,et al.  Molecular Cancer Molecular Portrait of Cisplatin Induced Response in Human Testis Cancer Cell Lines Based on Gene Expression Profiles , 2022 .

[43]  Tumorigenesis and Neoplastic Progression Atherosclerosis and Vascular Aging as Modifiers of Tumor Progression, Angiogenesis, and Responsiveness to Therapy , 2022 .